ArticleJAMA2016
Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.
7 registry-linked trialsAbstract readComment
In one paragraph
Article in JAMA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 265 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
265citing papers in PubMed, 8 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Home Use of MD-Logic Automated Insulin Delivery System: Safety and Efficacy
Evaluation of Minimed 670G Hybrid Closed Loop System On-Boarding Protocol, for Patients With Type 1 Diabetes on Multiple Daily Insulin Injection Therapy
Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump: A Comparison of Insulin Degludec to Continuous Subcutaneous Infusion of Insulin Aspart for Basal Insulin Delivery in Type 1 Diabetes
The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus in Patients With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM): a Cross-over Controlled Trial
Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D
Transition of Patients With T1D From Multiple Daily Injection (MDI) and Self-Monitoring of Blood Glucose (SMBG) Directly to MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) System :Impact on Glucose Control and Quality of Life Measures
Effect of Automated Insulin Delivery With Advanced Closed-loop on Glucose Outcomes and Early-stage Diabetic Complications
Who cites it
265 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Efficacy and Safety of iLet Bionic Pancreas in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta Analysis.Endocrinology, diabetes & metabolism · 2025Pooled it
- Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.Health technology assessment (Winchester, England) · 2024Pooled it
- Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data.PharmacoEconomics · 2024Pooled it
- Real-World Evidence of Automated Insulin Delivery System Use.Diabetes technology & therapeutics · 2024Pooled it
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Diabetes Technologies - Insulin Delivery.Hormone research in paediatrics · 2024Guideline
- Safety, metabolic and psychological outcomes of Medtronic MiniMed 670G in children, adolescents and young adults: a systematic review.European journal of pediatrics · 2023Pooled it
- A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ Technology in Youth and Adults from Age 2 to 72.Diabetes technology & therapeutics · 2023Pooled it
- Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis.Systematic reviews · 2020Pooled it
- Automated Insulin Delivery in Older Adults with Type 1 Diabetes.NEJM evidence · 2025Trial
- Hybrid Closed Loop Using a Do-It-Yourself Artificial Pancreas System in Adults With Type 1 Diabetes.Journal of diabetes science and technology · 2024Trial
- Assessment of Meal Anticipation for Improving Fully Automated Insulin Delivery in Adults With Type 1 Diabetes.Diabetes care · 2023Trial
- Integrating metabolic expenditure information from wearable fitness sensors into an AI-augmented automated insulin delivery system: a randomised clinical trial.The Lancet. Digital health · 2023Trial
- Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.Frontiers in endocrinology · 2023Trial
- The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes.Diabetes technology & therapeutics · 2022Trial
- A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes.Diabetes technology & therapeutics · 2022Trial
- A Multicenter Randomized Trial Evaluating the Insulin-Only Configuration of the Bionic Pancreas in Adults with Type 1 Diabetes.Diabetes technology & therapeutics · 2022Trial
- A Comparison of Postprandial Glucose Control in the Medtronic Advanced Hybrid Closed-Loop System Versus 670G.Diabetes technology & therapeutics · 2022Trial
- The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study.Journal of diabetes science and technology · 2022Trial
- Outpatient Randomized Crossover Automated Insulin Delivery Versus Conventional Therapy with Induced Stress Challenges.Diabetes technology & therapeutics · 2022Trial
- Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System.Diabetes technology & therapeutics · 2021Trial
205 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
- Comment on
- Comment on
Authors and funding
7 authors.
Richard M BergenstalInternational Diabetes Center, Minneapolis, Minnesota.
Satish GargBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora.
Stuart A WeinzimerYale University, New Haven, Connecticut.
Bruce A BuckinghamStanford University, Stanford, California.
Bruce W BodeAtlanta Diabetes Associates, Atlanta, Georgia.
William V TamborlaneYale University, New Haven, Connecticut.
Francine R KaufmanMedtronic, Northridge, California.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AlgorithmsBlood GlucoseDiabetes Mellitus, Type 1HumansHypoglycemic AgentsInsulinInsulin Infusion SystemsBlood GlucoseHypoglycemic AgentsInsulin
Identifiers
PMID
27629148What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03040414ClinicalTrials.gov
NCT03755479ClinicalTrials.gov
NCT04409587ClinicalTrials.gov
NCT04414579ClinicalTrials.gov
NCT04614623ClinicalTrials.gov
NCT04616391ClinicalTrials.gov
and 1 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.